None listed
Conditions
Interventions
Drug : This study was a prospective, randomized controlled trial comparing three oral eradication regimens in patients with clarithromycin-resistant Helicobacter pylori (H. pylori) infection. All medi
however, they differ in the choice of the second antibiotic. The PAM-B arm uses amoxicillin (1,000 mg
Sponsors
Dong-A University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Adults aged 18 to 80 years of both sexes. ? Patients diagnosed with Helicobacter pylori infection via endoscopy, confirmed by at least one of the following methods: histology, rapid urease test, serology, or urea breath test. ? Patients with clarithromycin resistance confirmed by dual-priming oligonucleotide polymerase chain reaction (DPO-PCR). ? Patients who provided written informed consent after receiving a full explanation of the study objectives and procedures.
Exclusion criteria
Exclusion criteria: ? Patients with a history of prior Helicobacter pylori eradication therapy. ? Patients with a history of gastric surgery (e.g., gastrectomy). ? Patients with severe hepatic or renal impairment. ? Patients with a history of antibiotic allergy. ? Patients who had taken antibiotics within 4 weeks prior to study enrollment. ? Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication success rate assessed by intention-to-treat (ITT) and per-protocol (PP) analyses | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of treatment-related adverse events during the eradication therapy period;Medication compliance during the eradication therapy period | — |
Countries
Korea, Republic of
Contacts
Public ContactMyeongseok Koh
Dong-A University Hospital
Outcome results
None listed